Coherus Oncology, Inc.
CHRS · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.05 | 0.04 | 1.61 | 0.01 |
| FCF Yield | -12.93% | -55.86% | -39.55% | -3.22% |
| EV / EBITDA | 5.43 | -3.57 | -4.04 | -4.63 |
| Quality | ||||
| ROIC | -66.31% | -67.15% | -91.20% | -57.47% |
| Gross Margin | 55.97% | 38.19% | 66.79% | 82.36% |
| Cash Conversion Ratio | -0.72 | 0.74 | 0.83 | 0.13 |
| Growth | ||||
| Revenue 3-Year CAGR | 8.15% | -7.64% | -23.74% | -2.84% |
| Free Cash Flow Growth | 88.33% | 27.96% | -527.99% | -126.32% |
| Safety | ||||
| Net Debt / EBITDA | 2.83 | -1.95 | -1.63 | -0.01 |
| Interest Coverage | -4.11 | -5.01 | -7.91 | -11.49 |
| Efficiency | ||||
| Inventory Turnover | 1.68 | 2.54 | 0.61 | 0.62 |
| Cash Conversion Cycle | 296.55 | 432.52 | 729.35 | 626.11 |